Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03105102 · ClinicalTrials.gov registry record · Phase 3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 1,336
- Enrollment target
- 20
- Study locations
NCT03105102 is a Phase 3 study of Crohn's Disease that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,336 participants, below the 2,382-participant average among 105 other Crohn's Disease trials with a reported enrollment target (44% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT03105102, a Phase 3 study of Crohn's Disease, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,336 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intravenous risankizumab induction treatment in Study M16-006 or Study M15-991; * Sub-study 2 (Randomized, exploratory maintenance study) to evaluate the efficacy and safety of two different dosing regimens for risankizumab as maintenance therapy in participants who responded to induction treatment in Study M16-006 or Study M15-991; * Sub-study 3 (Open-label, long-term extension study) to evaluate long-term safety of risankizumab in participants who completed Sub-study 1, Sub-study 2, another AbbVie risankizumab Crohn's disease study, or participants who responded to induction treatment in Study M16-006 or Study M15-991 with no final endoscopy due to the Covid-19 pandemic. Additional objectives are to further investigate long-term efficacy and tolerability of risankizumab; * Sub-study 4 (Open-label On Body Injector (OBI) administration and long-term extension study) to evaluate patient-reported outcomes, efficacy, safety, tolerability, and pharmacokinetics of risankizumab administered via OBI in participants who are receiving maintenance treatment with risankizumab. * OL CTE to ensure uninterrupted care in accordance with local regulations until risankizumab is commercially available for participants who completed Sub-study 3, Sub-study 4.
Conditions Studied
Interventions
- DRUG Placebo for Risankizumab SC
- DRUG Risankizumab IV
- DRUG Placebo for Risankizumab IV
- DRUG Risankizumab SC
- DRUG Risankizumab On-Body Injector (OBI)
Study Locations (20)
California
- Southern California Res. Ctr. /ID# 211991 - Coronado
- Duplicate_Newport Huntington Medical Group /ID# 213035 - Huntington Beach
- UC San Diego Health Systems /ID# 155555 - La Jolla
- United Medical Doctors /ID# 207888 - Los Alamitos
- TLC Clinical Research Inc /ID# 212719 - Los Angeles
- Gastrointestinal Biosciences Clinical Trials, LLC /ID# 162657 - Los Angeles
- United Medical Doctors - Murrieta /ID# 158300 - Murrieta
- University of California San Francisco - Mission Bay /ID# 157127 - San Francisco
- Duplicate_Cedars-Sinai Medical Center-West Hollywood /ID# 163839 - West Hollywood
Florida
- Brandon Premier Health Care, PA/Gulf Coast Research Group, LLC /ID# 162262 - Brandon
- South Lake Pain Institute, Inc /ID# 162808 - Clermont
- Omega Research Maitland, LLC /ID# 171082 - DeBary
- Universal Axon Clinical Research /ID# 165428 - Doral
Arizona
- Digestive Disease Consultants, A Division of Arizona Digestive Health, P.C /ID# 211884 - Mesa
- Phoenix VA Health Care System /ID# 162264 - Phoenix
- Banner - University Medical Center Tucson /ID# 158502 - Tucson
Colorado
- Peak Gastroenterology Associates, PC /ID# 165843 - Colorado Springs
- Rocky Mountain Pediatric Gastroenterology /ID# 207170 - Lone Tree
Arkansas
- Atria Clinical Research /ID# 164505 - Little Rock
Connecticut
- Duplicate_Western Connecticut Medical Group /ID# 165879 - Danbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,336 participants |
| Start Date | 2018-04-09 |
| Est. Completion | 2026-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03105102
The ClinicalTrials.gov registry entry for NCT03105102 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,336 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,382-participant average among 105 other Crohn's Disease trials with a reported enrollment target (44% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 5 interventions - of which Placebo for Risankizumab SC is the first listed.
NCT03105102 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT03105102 about?
NCT03105102 is a clinical study titled "A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease". The study consists of 4 sub-studies, as follows: * Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safety of risankizumab versus placebo as maintenance therapy in participants with moderately to severely active Crohn's disease (CD) who responded to intr...
What is the current status of trial NCT03105102?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,336 participants. The study started on 2018-04-09. Estimated completion is 2026-05.
What conditions does trial NCT03105102 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT03105102?
The interventions under investigation include: Placebo for Risankizumab SC (DRUG), Risankizumab IV (DRUG), Placebo for Risankizumab IV (DRUG), Risankizumab SC (DRUG), Risankizumab On-Body Injector (OBI) (DRUG).
Who is sponsoring clinical trial NCT03105102?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03105102 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.